Vital Transformation
@vitaltransform.bsky.social
Vital Transformation is a small, unique consultancy focused on addressing the challenges of today’s modern healthcare system. We partner with your organization to help you find answers to hard-to-solve problems.
Small‑molecule drugs face Medicare negotiations four years earlier than biologics, slashing early‑stage funding by nearly 70%. Affordable pills are disappearing, and vital therapies are at risk.
Read the PhRMA article: buff.ly/1mGUHHS
@weworkforhealth
Read the PhRMA article: buff.ly/1mGUHHS
@weworkforhealth
May 5, 2025 at 2:02 PM
Small‑molecule drugs face Medicare negotiations four years earlier than biologics, slashing early‑stage funding by nearly 70%. Affordable pills are disappearing, and vital therapies are at risk.
Read the PhRMA article: buff.ly/1mGUHHS
@weworkforhealth
Read the PhRMA article: buff.ly/1mGUHHS
@weworkforhealth
Early-stage small-molecule funding plunged 68% overall and 74% for high-Medicare-exposure programs, even as large-molecule investments rose ten times. Investors are shifting toward biologics under the IRA’s two-tier pricing.
Read: buff.ly/CrTmhOr
#IRA #DrugPricing #Pharma #Health #Research
Read: buff.ly/CrTmhOr
#IRA #DrugPricing #Pharma #Health #Research
home - Vital Transformation
The impact of health technology made simple...
buff.ly
May 2, 2025 at 1:03 PM
Early-stage small-molecule funding plunged 68% overall and 74% for high-Medicare-exposure programs, even as large-molecule investments rose ten times. Investors are shifting toward biologics under the IRA’s two-tier pricing.
Read: buff.ly/CrTmhOr
#IRA #DrugPricing #Pharma #Health #Research
Read: buff.ly/CrTmhOr
#IRA #DrugPricing #Pharma #Health #Research
Medicare’s nine-year price cap erodes ~40% of a small-molecule project’s value before trials, sidelining therapies for aging - extending it to 13 years would restore innovators’ financial runway.
Read more: buff.ly/4w5EV5P
#IRA #DrugPricing #Pharma #Health #Technology #Research #Economics
Read more: buff.ly/4w5EV5P
#IRA #DrugPricing #Pharma #Health #Technology #Research #Economics
May 1, 2025 at 1:03 PM
Medicare’s nine-year price cap erodes ~40% of a small-molecule project’s value before trials, sidelining therapies for aging - extending it to 13 years would restore innovators’ financial runway.
Read more: buff.ly/4w5EV5P
#IRA #DrugPricing #Pharma #Health #Technology #Research #Economics
Read more: buff.ly/4w5EV5P
#IRA #DrugPricing #Pharma #Health #Technology #Research #Economics
President Trump’s new order moves to end the IRA’s “pill penalty.” Our research shows median investment in key small-molecule therapies fell from $175M to $45M. The policy aims to bring that investment back: buff.ly/5oFWhrA
#IRA #DrugPricing #Pharma#Healthcare #Health #Research #Economics
#IRA #DrugPricing #Pharma#Healthcare #Health #Research #Economics
April 30, 2025 at 1:04 PM
President Trump’s new order moves to end the IRA’s “pill penalty.” Our research shows median investment in key small-molecule therapies fell from $175M to $45M. The policy aims to bring that investment back: buff.ly/5oFWhrA
#IRA #DrugPricing #Pharma#Healthcare #Health #Research #Economics
#IRA #DrugPricing #Pharma#Healthcare #Health #Research #Economics
Richard Z. Xie, Tess Cameron & Peter Kolchinsky show the IRA’s nine-year window wipes out small-molecule profits after Year 9, slashing NPV ~40%. Our analysis confirms this pill penalty deters critical small-molecule investment.
Read their report here: buff.ly/PV09eze
#IRA #DrugPricing #Pharma
Read their report here: buff.ly/PV09eze
#IRA #DrugPricing #Pharma
The Impact of the Inflation Reduction Act on Investment in Innovative Medicines: A Project-Level Analysis
buff.ly
April 29, 2025 at 1:05 PM
Richard Z. Xie, Tess Cameron & Peter Kolchinsky show the IRA’s nine-year window wipes out small-molecule profits after Year 9, slashing NPV ~40%. Our analysis confirms this pill penalty deters critical small-molecule investment.
Read their report here: buff.ly/PV09eze
#IRA #DrugPricing #Pharma
Read their report here: buff.ly/PV09eze
#IRA #DrugPricing #Pharma
Reuters reports the Trump administration aims to revise Medicare’s drug pricing timeline. Our research shows a 74% drop in NME investment post-IRA. Shorter pricing windows shift capital.
Reusters Report: buff.ly/gcqHOI5
VT Research: buff.ly/CrTmhOr
#IRA #DrugPricing #Pharma #Biopharma #Healthcare
Reusters Report: buff.ly/gcqHOI5
VT Research: buff.ly/CrTmhOr
#IRA #DrugPricing #Pharma #Biopharma #Healthcare
April 28, 2025 at 1:03 PM
Reuters reports the Trump administration aims to revise Medicare’s drug pricing timeline. Our research shows a 74% drop in NME investment post-IRA. Shorter pricing windows shift capital.
Reusters Report: buff.ly/gcqHOI5
VT Research: buff.ly/CrTmhOr
#IRA #DrugPricing #Pharma #Biopharma #Healthcare
Reusters Report: buff.ly/gcqHOI5
VT Research: buff.ly/CrTmhOr
#IRA #DrugPricing #Pharma #Biopharma #Healthcare
The IRA’s 9-year cap for small molecules and 13-year cap for biologics rerouted investment away from the pills seniors rely on. We sat down with Steve Usdin to unpack how this shift skews R&D incentives and future therapies.
Listen here: buff.ly/9ZuZR3K
#IRA #DrugPricing #Pharma #PillPenalty
Listen here: buff.ly/9ZuZR3K
#IRA #DrugPricing #Pharma #PillPenalty
April 27, 2025 at 1:01 PM
The IRA’s 9-year cap for small molecules and 13-year cap for biologics rerouted investment away from the pills seniors rely on. We sat down with Steve Usdin to unpack how this shift skews R&D incentives and future therapies.
Listen here: buff.ly/9ZuZR3K
#IRA #DrugPricing #Pharma #PillPenalty
Listen here: buff.ly/9ZuZR3K
#IRA #DrugPricing #Pharma #PillPenalty
We spoke with @steveusdin1 about the effects of IRA’s 9-year vs 13-year protection. Our research shows it channels early-stage funding to biologics over pills. Lower costs undermine future development
Listen to the full conversation: buff.ly/9ZuZR3K
@weworkforhealth #IRA #DrugPricing #PillPenalty
Listen to the full conversation: buff.ly/9ZuZR3K
@weworkforhealth #IRA #DrugPricing #PillPenalty
April 26, 2025 at 1:01 PM
We spoke with @steveusdin1 about the effects of IRA’s 9-year vs 13-year protection. Our research shows it channels early-stage funding to biologics over pills. Lower costs undermine future development
Listen to the full conversation: buff.ly/9ZuZR3K
@weworkforhealth #IRA #DrugPricing #PillPenalty
Listen to the full conversation: buff.ly/9ZuZR3K
@weworkforhealth #IRA #DrugPricing #PillPenalty
Steve Usdin explains how pharma is racing to fix the IRA’s “pill penalty.” We found median funding for senior-focused pills fell from $175 M to $45 M.
Usdin's BioCentury Article: buff.ly/L3GWSOo
Our conversation (4/8/25): buff.ly/9ZuZR3K
#IRA #DrugPricing #Pharma #Health #Technology #Research
Usdin's BioCentury Article: buff.ly/L3GWSOo
Our conversation (4/8/25): buff.ly/9ZuZR3K
#IRA #DrugPricing #Pharma #Health #Technology #Research
Steve Usdin: Tariffs, Price Controls, & Inflation Reduction Act (IRA) - Vital Health Podcast
In this episode, host Duane Schulthess sits down with Steve Usdin, Senior Washington Editor at BioCentury Publications since 1993 and one of the most cited experts on FDA regulation, Medicare policy…
buff.ly
April 25, 2025 at 6:03 PM
Steve Usdin explains how pharma is racing to fix the IRA’s “pill penalty.” We found median funding for senior-focused pills fell from $175 M to $45 M.
Usdin's BioCentury Article: buff.ly/L3GWSOo
Our conversation (4/8/25): buff.ly/9ZuZR3K
#IRA #DrugPricing #Pharma #Health #Technology #Research
Usdin's BioCentury Article: buff.ly/L3GWSOo
Our conversation (4/8/25): buff.ly/9ZuZR3K
#IRA #DrugPricing #Pharma #Health #Technology #Research
Early-stage trial launches dropped 35% after the IRA. The orange line shows the decline in activity, diverging from the pre-IRA trend. Our study connects this shift to reduced investment in small molecule innovation: buff.ly/lkhuOjP
#IRA #DrugPricing #Pharma #Biopharma #Health #PillPenalty
#IRA #DrugPricing #Pharma #Biopharma #Health #PillPenalty
April 25, 2025 at 1:05 PM
Early-stage trial launches dropped 35% after the IRA. The orange line shows the decline in activity, diverging from the pre-IRA trend. Our study connects this shift to reduced investment in small molecule innovation: buff.ly/lkhuOjP
#IRA #DrugPricing #Pharma #Biopharma #Health #PillPenalty
#IRA #DrugPricing #Pharma #Biopharma #Health #PillPenalty
Our research shows a 74% drop in median investment for small molecule therapies targeting Medicare-heavy populations since the IRA passed. Incubate Coalition's tracker confirms 49 research programs and 24 drugs discontinued.
Study: buff.ly/lkhuOjP
Tracker: buff.ly/1rCmIEi
#IRA #PillPenalty
Study: buff.ly/lkhuOjP
Tracker: buff.ly/1rCmIEi
#IRA #PillPenalty
Life Sciences Investment Tracker | Incubate Coalition
0 Research Programs Discontinued 0 Drugs Discontinued since passage of the Inflation Reduction Act News Updates ITIF: The IRA is negotiating the United States out of drug innovation Stifel report:…
buff.ly
April 24, 2025 at 5:04 PM
Our research shows a 74% drop in median investment for small molecule therapies targeting Medicare-heavy populations since the IRA passed. Incubate Coalition's tracker confirms 49 research programs and 24 drugs discontinued.
Study: buff.ly/lkhuOjP
Tracker: buff.ly/1rCmIEi
#IRA #PillPenalty
Study: buff.ly/lkhuOjP
Tracker: buff.ly/1rCmIEi
#IRA #PillPenalty
The IRA was meant to help seniors, but it’s decreasing early investment in treatments for age-related diseases. Small molecule therapies for conditions affecting largely Medicare patients saw a 74% drop in median investment.
More from We Work for Health: buff.ly/INAKWj9
#IRA #PillPenalty
More from We Work for Health: buff.ly/INAKWj9
#IRA #PillPenalty
April 23, 2025 at 5:03 PM
The IRA was meant to help seniors, but it’s decreasing early investment in treatments for age-related diseases. Small molecule therapies for conditions affecting largely Medicare patients saw a 74% drop in median investment.
More from We Work for Health: buff.ly/INAKWj9
#IRA #PillPenalty
More from We Work for Health: buff.ly/INAKWj9
#IRA #PillPenalty
New legislation would end the IRA’s “pill penalty,” which shortens the window for small-molecule drug pricing. Our research shows this policy led to a 74% drop in investment for treatments targeting seniors. Read more from No Patient Left Behind: buff.ly/gIiN51w.
#IRA #DrugPricing #PillPenalty
#IRA #DrugPricing #PillPenalty
Tillis Leads Legislation to Eliminate Biden’s “Pill Penalty,” Restore… | No Patient Left Behind
📢Thank you, Senators Tillis, Budd, and Daines for introducing legislation to eliminate the small molecule #PillPenalty. By imposing price controls on small molecules just nine years after FDA…
buff.ly
April 22, 2025 at 3:04 PM
New legislation would end the IRA’s “pill penalty,” which shortens the window for small-molecule drug pricing. Our research shows this policy led to a 74% drop in investment for treatments targeting seniors. Read more from No Patient Left Behind: buff.ly/gIiN51w.
#IRA #DrugPricing #PillPenalty
#IRA #DrugPricing #PillPenalty
Suneet Varma of Pfizer Oncology says IRA-related factors make biologics a more stable investment. Our research shows small molecule funding has dropped 68% since the law passed.
Read more: buff.ly/mDCX8Ws
#IRA #DrugPricing #Pharma #PillPenalty
Read more: buff.ly/mDCX8Ws
#IRA #DrugPricing #Pharma #PillPenalty
April 21, 2025 at 1:03 PM
Suneet Varma of Pfizer Oncology says IRA-related factors make biologics a more stable investment. Our research shows small molecule funding has dropped 68% since the law passed.
Read more: buff.ly/mDCX8Ws
#IRA #DrugPricing #Pharma #PillPenalty
Read more: buff.ly/mDCX8Ws
#IRA #DrugPricing #Pharma #PillPenalty
The IRA triggered a 74% drop in investment for pills treating Medicare patients. Alzheimer's, cancer, and other therapies are now at risk. Equal timelines could help restore progress.
📄https://buff.ly/Agz6GuJ
#IRA #DrugPricing #Pharma #PIllPenalty #Research
📄https://buff.ly/Agz6GuJ
#IRA #DrugPricing #Pharma #PIllPenalty #Research
April 18, 2025 at 6:02 PM
The IRA triggered a 74% drop in investment for pills treating Medicare patients. Alzheimer's, cancer, and other therapies are now at risk. Equal timelines could help restore progress.
📄https://buff.ly/Agz6GuJ
#IRA #DrugPricing #Pharma #PIllPenalty #Research
📄https://buff.ly/Agz6GuJ
#IRA #DrugPricing #Pharma #PIllPenalty #Research
Claims that the IRA wouldn’t affect innovation overlooked how early-stage investors really make decisions. Our research shows the pipeline for senior-focused therapies is already narrowing.
Read the full breakdown: buff.ly/MqJDp3K
#IRA #DrugPricing #Pharma #Healthcare #Health #PillPenalty
Read the full breakdown: buff.ly/MqJDp3K
#IRA #DrugPricing #Pharma #Healthcare #Health #PillPenalty
Inflation Reduction Act – Two Years On Investor Behavior, R&D Impacts, & Proposed Solutions - Vital Transformation
IRA has led to: A 35% reduction in early-stage phase I and II therapies under development from 2021-2023 among small and midsize biotech companies as measured from IRA’s introduction; the average…
buff.ly
April 18, 2025 at 1:03 PM
Claims that the IRA wouldn’t affect innovation overlooked how early-stage investors really make decisions. Our research shows the pipeline for senior-focused therapies is already narrowing.
Read the full breakdown: buff.ly/MqJDp3K
#IRA #DrugPricing #Pharma #Healthcare #Health #PillPenalty
Read the full breakdown: buff.ly/MqJDp3K
#IRA #DrugPricing #Pharma #Healthcare #Health #PillPenalty
The IRA sets Medicare’s maximum fair price at year 9 for small molecule drugs, 4 years sooner than for biologics.
Since then, early-stage small molecule funding has dropped from $2B to $640M. Expect fewer new treatments for seniors by 2030. Read more: buff.ly/mDCX8Ws
Since then, early-stage small molecule funding has dropped from $2B to $640M. Expect fewer new treatments for seniors by 2030. Read more: buff.ly/mDCX8Ws
April 17, 2025 at 6:02 PM
The IRA sets Medicare’s maximum fair price at year 9 for small molecule drugs, 4 years sooner than for biologics.
Since then, early-stage small molecule funding has dropped from $2B to $640M. Expect fewer new treatments for seniors by 2030. Read more: buff.ly/mDCX8Ws
Since then, early-stage small molecule funding has dropped from $2B to $640M. Expect fewer new treatments for seniors by 2030. Read more: buff.ly/mDCX8Ws
Two lemonade stands.
One caps prices after 13 weeks, the other after 9.
Same cost, less time; investors walk away from the latter.
That’s the pill penalty in the IRA; It’s pushing investment away from small molecules.
📄 Full analysis: buff.ly/MqJDp3K
#IRA #DrugPricing #Pharma #PillPenalty
One caps prices after 13 weeks, the other after 9.
Same cost, less time; investors walk away from the latter.
That’s the pill penalty in the IRA; It’s pushing investment away from small molecules.
📄 Full analysis: buff.ly/MqJDp3K
#IRA #DrugPricing #Pharma #PillPenalty
Inflation Reduction Act – Two Years On Investor Behavior, R&D Impacts, & Proposed Solutions - Vital Transformation
IRA has led to: A 35% reduction in early-stage phase I and II therapies under development from 2021-2023 among small and midsize biotech companies as measured from IRA’s introduction; the average…
buff.ly
April 17, 2025 at 1:02 PM
Two lemonade stands.
One caps prices after 13 weeks, the other after 9.
Same cost, less time; investors walk away from the latter.
That’s the pill penalty in the IRA; It’s pushing investment away from small molecules.
📄 Full analysis: buff.ly/MqJDp3K
#IRA #DrugPricing #Pharma #PillPenalty
One caps prices after 13 weeks, the other after 9.
Same cost, less time; investors walk away from the latter.
That’s the pill penalty in the IRA; It’s pushing investment away from small molecules.
📄 Full analysis: buff.ly/MqJDp3K
#IRA #DrugPricing #Pharma #PillPenalty
Pills and tablets save lives.
The IRA changed how drugs are priced.
Investors had less time to profit, so they pulled back fast.
Drug development slowed across the industry.
Fewer new medicines are being made.
Patients — especially seniors — are losing out.
📄 Press release: buff.ly/zDkO8zv
The IRA changed how drugs are priced.
Investors had less time to profit, so they pulled back fast.
Drug development slowed across the industry.
Fewer new medicines are being made.
Patients — especially seniors — are losing out.
📄 Press release: buff.ly/zDkO8zv
April 16, 2025 at 7:03 PM
Pills and tablets save lives.
The IRA changed how drugs are priced.
Investors had less time to profit, so they pulled back fast.
Drug development slowed across the industry.
Fewer new medicines are being made.
Patients — especially seniors — are losing out.
📄 Press release: buff.ly/zDkO8zv
The IRA changed how drugs are priced.
Investors had less time to profit, so they pulled back fast.
Drug development slowed across the industry.
Fewer new medicines are being made.
Patients — especially seniors — are losing out.
📄 Press release: buff.ly/zDkO8zv
The EPIC Act (H.R. 1492) addresses the IRA’s “pill penalty,” which cuts exclusivity for small molecule drugs by stalling innovation and early investment.
Our IRA Research: buff.ly/mDCX8Ws
EPIC Act details from We Work for Health: buff.ly/PGouIbN
Our IRA Research: buff.ly/mDCX8Ws
EPIC Act details from We Work for Health: buff.ly/PGouIbN
The Inflation Reduction Act’s Impact Upon Early-Stage Venture Capital Investments - Therapeutic Innovation & Regulatory Science
Background The Congressional Budget Office has stated there is no evidence of a systematic decrease in the percentage of venture capital flowing to pharmaceutical companies since IRA’s passage. This…
buff.ly
April 16, 2025 at 1:02 PM
The EPIC Act (H.R. 1492) addresses the IRA’s “pill penalty,” which cuts exclusivity for small molecule drugs by stalling innovation and early investment.
Our IRA Research: buff.ly/mDCX8Ws
EPIC Act details from We Work for Health: buff.ly/PGouIbN
Our IRA Research: buff.ly/mDCX8Ws
EPIC Act details from We Work for Health: buff.ly/PGouIbN
Why has early-stage funding for small molecule drugs dropped 68%, from $2B to $640M?
The IRA’s 9-year price-setting window shortens their return period, increasing risk and driving early-stage capital elsewhere.
Read our latest findings: buff.ly/mDCX8Ws
#IRA #DrugPricing #Pharma #Health
The IRA’s 9-year price-setting window shortens their return period, increasing risk and driving early-stage capital elsewhere.
Read our latest findings: buff.ly/mDCX8Ws
#IRA #DrugPricing #Pharma #Health
April 15, 2025 at 7:01 PM
Why has early-stage funding for small molecule drugs dropped 68%, from $2B to $640M?
The IRA’s 9-year price-setting window shortens their return period, increasing risk and driving early-stage capital elsewhere.
Read our latest findings: buff.ly/mDCX8Ws
#IRA #DrugPricing #Pharma #Health
The IRA’s 9-year price-setting window shortens their return period, increasing risk and driving early-stage capital elsewhere.
Read our latest findings: buff.ly/mDCX8Ws
#IRA #DrugPricing #Pharma #Health
Our new data shows small molecule investment has dropped 68%, 74% for Medicare-focused treatments, since the IRA was introduced.
Removing the pill penalty could boost FDA approvals by 21%.
Read more from We Work for Health: buff.ly/Didvv88
#IRA #DrugPricing #Pharma #Biopharma #HealthTech #Health
Removing the pill penalty could boost FDA approvals by 21%.
Read more from We Work for Health: buff.ly/Didvv88
#IRA #DrugPricing #Pharma #Biopharma #HealthTech #Health
April 15, 2025 at 1:02 PM
Our new data shows small molecule investment has dropped 68%, 74% for Medicare-focused treatments, since the IRA was introduced.
Removing the pill penalty could boost FDA approvals by 21%.
Read more from We Work for Health: buff.ly/Didvv88
#IRA #DrugPricing #Pharma #Biopharma #HealthTech #Health
Removing the pill penalty could boost FDA approvals by 21%.
Read more from We Work for Health: buff.ly/Didvv88
#IRA #DrugPricing #Pharma #Biopharma #HealthTech #Health
@DuaneSchulthess explains how the IRA’s evolution from Build Back Better is impacting small-molecule drug development. VT’s research shows innovation is declining—The EPIC Act could help. Watch here: buff.ly/8XEovVm
#IRA #Pharma #Health #Research @weworkforhealth
#IRA #Pharma #Health #Research @weworkforhealth
buff.ly
April 14, 2025 at 8:00 PM
@DuaneSchulthess explains how the IRA’s evolution from Build Back Better is impacting small-molecule drug development. VT’s research shows innovation is declining—The EPIC Act could help. Watch here: buff.ly/8XEovVm
#IRA #Pharma #Health #Research @weworkforhealth
#IRA #Pharma #Health #Research @weworkforhealth
📢 New VT Research!
The IRA is driving a 68% aggregate drop in early-stage funding for small molecule drugs, with early-stage clinical trials also in decline. Our latest report shows how this puts future treatments for seniors at risk.
Read more: buff.ly/pkV8vHB
#IRA #DrugPricing #Pharma #Health
The IRA is driving a 68% aggregate drop in early-stage funding for small molecule drugs, with early-stage clinical trials also in decline. Our latest report shows how this puts future treatments for seniors at risk.
Read more: buff.ly/pkV8vHB
#IRA #DrugPricing #Pharma #Health
April 14, 2025 at 3:02 PM
📢 New VT Research!
The IRA is driving a 68% aggregate drop in early-stage funding for small molecule drugs, with early-stage clinical trials also in decline. Our latest report shows how this puts future treatments for seniors at risk.
Read more: buff.ly/pkV8vHB
#IRA #DrugPricing #Pharma #Health
The IRA is driving a 68% aggregate drop in early-stage funding for small molecule drugs, with early-stage clinical trials also in decline. Our latest report shows how this puts future treatments for seniors at risk.
Read more: buff.ly/pkV8vHB
#IRA #DrugPricing #Pharma #Health
The IRA is creating consequences for patients and innovation. By imposing earlier price controls on certain medicines, it discourages investment in small molecules, leading to fewer options and higher costs for patients.
Read more from the CAHC: buff.ly/xCnZcWX
Read more from the CAHC: buff.ly/xCnZcWX
April 13, 2025 at 2:03 PM
The IRA is creating consequences for patients and innovation. By imposing earlier price controls on certain medicines, it discourages investment in small molecules, leading to fewer options and higher costs for patients.
Read more from the CAHC: buff.ly/xCnZcWX
Read more from the CAHC: buff.ly/xCnZcWX